Безопасность кардиоселективных бета-адреноблокаторов для лечения кардиоваскулярной патологии у пациентов с хроническими обструктивными заболеваниями легких

Б. В. Трапезникова, Э. А. Ильина, Valery Feofanovich Ushakov · Russian Cardiology Journal (Russian Cardiology Society) · 2010

The review is focused on the use of cardio-selective beta-adrenoblockers (BAB) in patients with cardiovascular disease combined with chronic obstructive pulmonary disease (COPD).The data of meta-analyses, clinical trials and reviews are presented, which demonstrate cardio-selective BAB safety in COPD patients.In addition, all-cause and cardiovascular mortality in COPD patients, as well as cardio-selective BAB effects on these mortality parameters, are discussed.Key words: Chronic obstructive pulmonary disease, asthma, cardiovascular morbidity and mortality, cardio-selective beta-adrenoblockers, safety, FEV1.

Cited by 0 works. doi:10.15829/1560-4071-2010-3-80-85 Open-access PDF

Authors